LLY — Eli Lilly and Company stock price, charts and financials

QT72Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
1217.73
+32.02+2.70%
LLYQT72Eli Lilly and Company·NYSE
1217.73+2.70%
News
Up 2.7% — Eli Lilly and Company Q2 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E39.72EPS (ttm)29.85Insider Own10.29%Shs Outstand941.74MPerf Week3.21%
Market Cap1.12TForward P/E25.68EPS next Y46.17Insider Trans-0.02%Shs Float848.69MPerf Month-2.57%
Enterprise Value1.16TPEG0.42EPS next Q-Inst Own82.40%Short Float1.21%Perf Quarter21.62%
Income28.14BP/S14.02EPS this Y28.36%Inst Trans-Short Ratio3.14Perf Half Y16.15%
Sales79.67BP/B31.23EPS next Y27.78%ROA18.77%Short Interest10.28MPerf YTD10.33%
Book/sh-P/C37.68EPS next 5Y15.84%ROE92.58%52W High1283.17 -5.10%Perf Year58.86%
Cash/sh-P/FCF55.68EPS past 3/5Y51.73% 28.82%ROIC27.38%52W Low640.64 90.08%Perf 3Y160.89%
Dividend Est.6.92 (0.57%)EV/EBITDA33.02Sales past 3/5Y31.69% 21.58%Gross Margin84.01%Volatility4.38% 3.10%Perf 5Y386.94%
Dividend TTM6.46 (0.53%)EV/Sales14.59EPS Y/Y TTM140.39%Oper. Margin43.92%ATR (14)42.27Perf 10Y1329.77%
Dividend Ex-DateAug 14, 2026Quick Ratio1.00Sales Y/Y TTM60.40%Profit Margin33.53%RSI (14)53.71Recom2.33
Dividend Gr. 3/5Y15.24% 15.18%Current Ratio1.35EPS Q/Q155.99%SMA201.24%Beta0.50Target Price1333.29
Payout21.66%Debt/Eq1.62Sales Q/Q55.54%SMA502.43%Rel Volume0.84Prev Close1185.71
Employees50,000LT Debt/Eq1.54EarningsOct 29SMA20014.74%Avg Volume3.05MPrice1217.73
IPO DateJun 01, 1972Option/ShortYes / YesEPS/Sales Surpr.22.64% 11.11%Net Debt/EBITDA1.31Volume2,568,744Change2.70%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedUBSBuy$1.00$1376
Aug-06-26ReiteratedMorgan StanleyOverweight$1.00$1419
Aug-06-26ReiteratedWells FargoOverweight$1280$1330
Aug-06-26ReiteratedBMO CapitalOutperform$1300$1400
Aug-06-26ReiteratedCantor FitzgeraldOverweight$1350$1410
Jul-14-26ReiteratedBernsteinOutperform$1300$1385
Jul-13-26ReiteratedUBSBuy$1370$1425
Jul-13-26ReiteratedGuggenheimBuy$1161$1273
Jul-09-26ReiteratedUBSBuy$1.00$1370
Jul-08-26ReiteratedRBC CapitalOutperform$1250$1500
Latest News
Aug-08-26
Aug-07-26
Aug-06-26
Aug-05-26
Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Ownership
Total institutional ownership82.40%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue79,66665,17945,043
Cost of Goods Sold Incl. D&A12,73710,5648,418
Gross Profit66,92954,61536,624
Selling, General and Administrative Excl. Other12,44911,0948,132
Research and Development14,59713,33810,991
Other Operating Expense4,8934870
Operating Income34,98929,69617,502
Interest Expense980795781
Unusual Expense
Non-Operating Income (Expense)-415-3,171-4,041
Net Income Before Taxes33,59425,73012,680
Income Taxes6,8855,0922,090
Consolidated Net Income26,71020,63810,590
Net Income From Continuing Operations26,71020,63810,590
Net Income26,71020,63810,590
EPS (Recurring)29.8523.0011.76
EPS (Basic, Before Extraordinaries)29.8523.0011.76
EPS (Diluted)29.8022.9511.71
EBITDA35,20827,93715,228
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio40.8646.8365.93
Price To Sales Ratio13.6314.8115.44
Gross Margin84.0183.7981.31
Operating Margin43.9245.5638.86
Net Margin33.5331.6623.51
Shares Outstanding892898901
Market Capitalization1,086,215965,063695,572
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$1327.05$1128.83$930.61$732.38$534.16 Close Price0.00M19364.98M38729.96M58094.95M77459.93MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Seymour MelissaEVP, Global QualityAug 01 '26Option Exercise0.0098101,506Aug 03
Yuffa IlyaEVP&Pres, LLY USA&Global CapabJun 10 '26Sale1150.772,5002,876,92529,804Jun 11
LILLY ENDOWMENT INCother: Former 10% ShareholderMay 06 '26Sale995.3615,82815,754,53791,881,150May 07
Zakrowski Donald ASVP, Finance, & CAOFeb 16 '26Option Exercise0.0018403,607Feb 18
Montarce LucasEVP & CFOFeb 16 '26Option Exercise0.00368016,418Feb 18
Custer Kenneth L.EVP & President, Card Met HlthFeb 16 '26Option Exercise0.00207010,232Feb 18
Brown Adrienne SEVP, President LLY ImmFeb 16 '26Option Exercise0.0039105,312Feb 18
Van Naarden JacobEVP,Pres LLY Oncology&HdCorpBDFeb 01 '26Option Exercise0.004,108024,670Feb 03
Yuffa IlyaEVP&Pres, LLY USA&Global CapabFeb 01 '26Option Exercise0.003,394029,654Feb 03
Skovronsky DanielEVP, CS&PO & Pres. LRLFeb 01 '26Option Exercise0.0012,6840150,165Feb 03
Ricks David APresident, Chair, and CEOFeb 01 '26Option Exercise0.0031,9320547,098Feb 03
Rau DiogoEVP & CIDOFeb 01 '26Option Exercise0.003,752023,471Feb 03
Jonsson PatrikEVP & President, LLY Int'lFeb 01 '26Option Exercise0.003,930057,581Feb 03
Hernandez EdgardoEVP & Pres., Mfg. OperationsFeb 01 '26Option Exercise0.003,572043,303Feb 03
Hakim AnatEVP, GC & SecretaryFeb 01 '26Option Exercise0.006,700017,663Feb 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.